for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Vir, Alnylam pick coronavirus therapy candidate, plan human trials by year end

May 4 (Reuters) - Vir Biotechnology Inc and Alnylam Pharmaceuticals Inc have identified a drug candidate for treating COVID-19 and plan to begin human testing by the end of the year, the companies said on Monday.

The therapy candidate makes use of gene-silencing RNA interference (RNAi) technology that targets and “silences” specific genetic material, blocking the production of deadly proteins that cause diseases. (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shounak Dasgupta)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up